Borris L C, Lassen M R
Department of Orthopaedics, Aalborg Hospital, Denmark.
Drug Saf. 1995 Jan;12(1):26-31. doi: 10.2165/00002018-199512010-00002.
On the basis of the results of the 11 studies reviewed, thromboprophylaxis with unfractionated heparin, low molecular weight (LMW) heparin or a heparinoid (danaparoid sodium; Org 10172) in patients undergoing total hip replacement did not show any important clinical differences with respect to the tolerability profiles of the different compounds. However, as a result of the great variability in the presentation and evaluation of blood losses and bleeding complications in these studies, it is mandatory to perform a direct comparison of the different compounds in question in a double-blind, prospective clinical study.
根据所综述的11项研究结果，在接受全髋关节置换术的患者中，使用普通肝素、低分子量（LMW）肝素或类肝素（达那肝素钠；Org 10172）进行血栓预防，在不同化合物的耐受性方面未显示出任何重要的临床差异。然而，由于这些研究中失血和出血并发症的呈现和评估存在很大差异，必须在一项双盲前瞻性临床研究中对相关不同化合物进行直接比较。
